3-amin3-arylpropan-1-ol compounds, their preparation and use
    31.
    发明授权
    3-amin3-arylpropan-1-ol compounds, their preparation and use 失效
    3-氨基-3-芳基丙-1-醇化合物,其制备和用途

    公开(公告)号:US06410790B1

    公开(公告)日:2002-06-25

    申请号:US09545371

    申请日:2000-04-07

    IPC分类号: C07C21100

    摘要: 3-amino-3-arylpropan-1-ol compounds of formula I: R1 and R2 independently denoting C1-6 alkyl, or together denoting a (CH2)2-6 ring optionally substituted by phenyl, R3 denoting C3-6 alkyl, C3-6 cycloalkyl, aryl optionally containing heteroatoms and optionally substituted by R6 to R8, or a substituted C1-3 alkylphenyl of formula XII:  R4 and R5 independently denoting C1-6 alkyl, C3-6 cycloalkyl, phenyl, benzyl, or phenethyl, or together forming a (CH2)3-6 or CH2CH2OCH2CH2 ring, R6 to R8 independently denoting H, F, Cl, Br, CHF2, CF3, OH, OCF3, OR14, NR15R16, SR14, phenyl, SO2CH3, SO2CF3, C1-6 alkyl, CN, COOR14, or CONR15R16, or together forming a OCH2O, OCH2CH2O, CH═CHO, CH═C(CH3)O or (CH2)4 ring, R14 denoting C1-6 alkyl, phenyl, benzyl, or phenethyl, R15 and R16 independently denoting H, C1-6 alkyl, phenyl, benzyl or phenethyl, and A denoting optionally substituted aryl optionally containing heteroatoms, or a diastereomer or enantiomer or pharmaceutically acceptable salt thereof, and their preparation and use in pharmaceutical compositions.

    摘要翻译: 式I的3-氨基-3-芳基丙-1-醇化合物:R 1和R 2独立地表示C 1-6烷基,或一起表示任选被苯基取代的(CH 2)2-6环,R 3表示C 3-6烷基,C 3 -6环烷基,任选含有杂原子并任选被R 6至R 8取代的芳基或式XII的取代的C 1-3烷基苯基:R 4和R 5独立地表示C 1-6烷基,C 3-6环烷基,苯基,苄基或苯乙基,或 一起形成(CH2)3-6或CH2CH2OCH2CH2环,R6至R8独立地表示H,F,Cl,Br,CHF2,CF3,OH,OCF3,OR14,NR15R16,SR14,苯基,SO2CH3,SO2CF3,C1-6烷基 ,CN,COOR 14或CONR 15 R 16,或一起形成OCH 2 O,OCH 2 CH 2 O,CH = CHO,CH = C(CH 3)O或(CH 2)4环,R 14表示C 1-6烷基,苯基,苄基或苯乙基,R 15和 R16独立地表示H,C 1-6烷基,苯基,苄基或苯乙基,A表示任选地含有杂原子的任选取代的芳基,或其非对映异构体或对映异构体或其药学上可接受的盐, 在药物组合物中的应用和用途。

    Substituted oxadiazole compounds and their use as opioid receptor ligands
    34.
    发明授权
    Substituted oxadiazole compounds and their use as opioid receptor ligands 有权
    取代的恶二唑化合物及其作为阿片受体配体的用途

    公开(公告)号:US07589113B2

    公开(公告)日:2009-09-15

    申请号:US12143550

    申请日:2008-06-20

    摘要: Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.

    摘要翻译: 对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。

    SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS
    36.
    发明申请
    SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS 有权
    取代的奥沙利多化合物及其作为阿片受体配体的用途

    公开(公告)号:US20090005427A1

    公开(公告)日:2009-01-01

    申请号:US12143550

    申请日:2008-06-20

    摘要: Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.

    摘要翻译: 对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。